Topics covered in EBM include: Anatomy/Pathology; Biochemistry and Molecular Biology; Cell and Developmental Biology; Endocrinology and Nutrition; Immunology/Microbiology/Virology; Neuroscience; Pharmacology and Toxicology; Physiology; Bioimaging; Biomedical Engineering; Bionanoscience; Genomics, Proteomics, and Bioinformatics; Stem Cell Biology; Systems Biology, and Translational Research.
This journal is a member of the Committee on Publication Ethics (COPE)
Experimental Biology and Medicine (EBM) is a peer-reviewed journal dedicated to the publication of multidisciplinary and interdisciplinary research in the biomedical sciences. Published monthly, EBM provides both research and review articles as well as meeting symposia and brief communications. Articles in EBM represent cutting edge research at the overlapping junctions of the biological, physical and engineering sciences that impact upon the health and welfare of the world's population.
Topics covered in Experimental Biology and Medicine include: Anatomy/Pathology; Biochemistry and Molecular Biology; Cell and Developmental Biology; Endocrinology and Nutrition; Immunology/Microbiology/Virology; Neuroscience; Pharmacology and Toxicology; Physiology; Bioimaging; Biomedical Engineering; Bionanoscience; Genomics, Proteomics, and Bioinformatics; Stem Cell Biology; Systems Biology, and Translational Research.
|Ian S. Zagon, PhD||Pennsylvania State University, USA|
|William Allen Banks, MD||VA Puget Sound Health Care System, USA|
|Lynda Bonewald, PhD||University of Kansas, Missouri, USA|
|Beverley Greenwood-Van Meerveld, PhD||The University of Oklahoma, College of Medicine, USA|
|Alexander V. Ljubimov, PhD, DSc,||Cedars-Sinai Med Ctr, Los Angeles, USA|
|Patricia J. McLaughlin, DEd||Pennsylvania State University, USA|
|Douglas F. Paulsen, PhD||Morehouse School of Medicine, USA|
|Frederick J. Seidler||Duke University Medical Center, USA|
|Theodore Slotkin, PhD||Duke University Medical Center|
|R. Alberto Travagli||Penn State Hershey Medical Center, USA|
|Frans A. Kuypers, PhD||Children’s Hospital Oakland Research Institute, USA|
|Nancy M. Dahms, PhD||Medical College of Wisconsin, USA|
|Shyamal D. Desai, PhD||Louisiana State University Health Sciences Center, USA|
|Paulo A. Ferreira, PhD||Duke University Medical Center, USA|
|Witold Korytowski, PhD||Medical College of Wisconsin, USA|
|Muriel W. Lambert, PhD||New Jersey Medical School, USA|
|Shigemi Matsuyama, DVM, PhD||Case Western Reserve University, USA|
|Aleksander F. Sikorski, PhD||University of Wroclaw, Poland|
|Peter J. Stambrook, PhD||University of Cincinnati Medical Center, USA|
|Nan-Shan Chang, MD||National Cheng Kung University Medical College|
|David A. Dean, PhD||Northwestern University Medical School, USA|
|Stephen C. Ekker, PHD||Mayo Clinic College of Medicine, USA|
|Wei-Qiang Gao, PhD|
|Leszek Kotula, MD||New York Blood Center, USA|
|Shelly C. Lu, MD||University of California, Los Angeles, USA|
|Brandt L. Schneider, PhD||Texas Tech University HSC, USA|
|Yu-jui Yvonne Wan, PhD||UC Davis Medical Center, California, USA|
|Danna B. Zimmer, PhD||Texas A&M University|
|Warren E. Zimmer, PhD||Texas A&M University|
|Sam Dagogo-Jack, MD||University of Tennessee Health Science Center, USA|
|Lin He, PhD||Shanghai Jiao Tong University, China|
|Charles Chaffin, PhD||University of Maryland, USA|
|Ayotunde O. Dokun, MD, PhD||University of Virginia, USA|
|Riccarda Granata, PhD||University of Turin, Italy|
|Mykola D. Khalangot, MD, PhD, ScD||Komisarenko Institute Of Endocrinology And Metabolism, Ukraine|
|Radko Komers, MD, PhD||Oregon Health & Science University, USA|
|B.L. Gregoire Nyomba, MD, PhD||University of Manitoba, Canada|
|Elias S. Siraj, MD||Temple University School of Medicine, USA|
|Eugene Sobngwi, MD, MPh, PhD||University of Yaounde 1, Cameroon, Africa|
|Nancy D. Turner, PhD||Texas A&M University, USA|
|Weiqun (George) Wang, PhD||Kansas State University, USA|
|Linda Barber, PhD||King's College London, UK|
|Georg Behrens, MD||Hannover Medical School, Germany|
|Andrea Doria, MD||University of Padova, Italy|
|Farzin Farzaneh, PhD||King's College London, UK|
|George Fu Gao, DPh||Chinese Academy of Sciences, China|
|Kam Man Hui, PhD||National Cancer Centre Singapore|
|Yoshio Koyanagi, MD, PhD||Institute for Virus Research, Kyoto University, Japan|
|Jacques-Olivier Pers, PhD||CHRU Morvan, France|
|Maria C. Villacres, PhD||University of Southern California|
|Francois Villinger, PhD||Emory University|
|Steven L. Youngentob, PhD||The University of Tennessee Health Science Center, USA|
|Santosh D'Mello, PhD||The University of Texas at Dallas, USA|
|Terrence Deak, PhD||Binghamton University, USA|
|Alvaro Estevez, PhD||Cornell Medical Research Institute, New York, USA|
|James Hewett, PhD||Syracuse University, USA|
|Sandra J. Hewett, PhD||Syracuse University, USA|
|Kenneth S. Kosik, MD||University of California, Santa Barbara, USA|
|Frank A. Middleton, PhD||SUNY Upstate Medical University, USA|
|Sandra Mooney, PhD||University of Maryland, USA|
|Gregg D. Stanwood, PhD|
|Mingqing Xu, PhD||Shanghai Jiao Tong University, China|
|Y. James Kang, DVM, PhD||Sichuan University West China Hospital, China|
|Boon Huat Bay, MD||National University of Singapore|
|Wen-Xing Ding, PhD||University of Kansas Medical Center, USA|
|Min Hee Kang, PhD||Texas Tech University HSC, USA|
|Wei Zheng, PhD||Purdue University, USA|
|Zhanxiang Zhou, PhD||University of Louisville, USA|
|Robert T. Mallet, PhD||University of North Texas, USA|
|R. Todd Alexander||University of Alberta, Canada|
|Frantisek Kolar, PhD||Academy of Sciences of the Czech Republic|
|Rong Ma, MD||University of North Texas Health Science Center|
|Jiri Pacha, PhD||Academy of Sciences of Czech Republic|
|Shaw-Jeng Tsai, PhD||National Cheng-Kung University Medical College, Taiwan|
|Samuel Verges, PhD||Hopital SUD, France|
|Tobias Wang, PhD||Aarhus University, Denmark|
|Lei Xi, MD|
|Shaohua Yang, MD, PhD||University of North Texas Health Science Center, USA|
|Chunyu Zeng, MD||The Third Military Medical University, China|
|YongKeun Park, PhD||Korea Advanced Institute of Science & Technology, Korea|
|Sanjiv Sam Gambhir, MD, PhD||Stanford University, Palo Alto, California, USA|
|Ignacy Gryczynski, PhD||University of North Texas Health Science Center, USA|
|Zygmunt (Karol) Gryczynski, PhD||University of North Texas Health Science Center, USA|
|Hong Liu, PhD|
|Kate Luby-Phelphs, PhD||University of Texas Southwestern Medical Center, USA|
|Qingming Luo, PhD||Huazhong University of Science & Technology, Wuhan, China|
|Andreea Trache, PhD|
|Simon C. Watkins, PhD||University of Pittsburgh, USA|
|Horst A. von Recum, PhD||Case Western Reserve University, USA|
|Eun Ji Chung, PhD||University of Southern California, USA|
|Stuart L. Cooper, USA||The Ohio State University, USA|
|F. Kurtis Kasper, PhD||Rice University|
|Kam W. Leong, PhD|
|William R. Wagner||University of Pittsburgh, USA|
|Juan Andres Melendez, PhD||SUNY – Polytechnic Institute, USA|
|Hassan A. N. El-Fawal, PhD||Albany College of Pharmacy & Health Sciences, USA|
|Jonathan Lovell, PhD||University of Buffalo, USA|
|Gabriel A. Silva,PhD||University of California, San Diego, USA|
|Ya-Ping Sun, PhD||Clemson University, USA|
|M. Silvina Tomassone, PhD||Rutgers University, USA|
|Jie Zheng, PhD||The University of Texas at Dallas, USA|
|Sulev Koks, MD, PhD||University of Tartu, Estonia|
|Robert W. Williams, PhD||University of Tennessee HSC, USA|
|Mark Geraci, MD||University of Colorado, USA|
|Stephen J. Glatt, PhD||SUNY Upstate Medical University, USA|
|James Lyons-Weiler, PhD||University of Pittsburgh|
|Momar Ndao, DVM, PhD|
|Heinrich Roder, PhD||Fox Chase Cancer Center, USA|
|Jian Feng, PhD||State University of New York at Buffalo, USA|
|Vania Broccoli, PhD||San Raffaele Scientific Institute, Milano, Italy|
|Jose Cibelli, PhD||Michigan State University, USA|
|Miguel A. Estaban, MD, PhD||Guangzhou Institutes of Biomedicine and Health|
|Guoping Fan||University of California, Los Angeles, USA|
|Meri T. Firpo, PhD||University of Minnesota|
|Antonis Hatzopoulos, PhD||Vanderbilt University, USA|
|Yoon-Young Jang, MD, PhD||Johns Hopkins University School of Medicine, USA|
|Dan S. Kaufman, MD, PhD||University of Minnesota, USA|
|Mark Mercola, PhD||Burnham Institute for Medical Research, La Jolla, California|
|Steven Stice, PhD||University of Georgia, USA|
|Ren-He Xu, MD, PhD|
|John P. Wikswo, PhD||Vanderbilt University, USA|
|Rashid Bashir, PhD||University of Illinois, Urbana-Champaign, USA|
|Richard A. Gray, PhD||The University of Alabama at Birmingham, USA|
|Rashi Iyer, PhD||Los Alamos National Laboratory, USA|
|Philip R. LeDuc, MD||Carnegie Melon University, USA|
|Andre Levchenko, PhD||Yale Systems Biology Institute, USA|
|D. Lansing Taylor, PhD||University of Pittsburgh Drug Discovery Institute, USA|
|Gordana Vunjak-Novakovic, PhD||Columbia University New York City, USA|
|Katrin Zeilinger, DVM||Charité-Universitätsmedizin Berlin, Germany|
|Thomas B. Thompson, PhD||University of Cincinnati College of Medicine, USA|
|Andrew P. Hinck, PhD||University of Pittsburgh, USA|
|James R. Horn, PhD||Northern Illinois University, USA|
|Douglas John Kojetin, PhD||Scripps Florida, USA|
|Rhett A. Kovall||University of Cincinnati College of Medicine, USA|
|Andrew M. Gulick||Hauptman-Woodward Medical Research Institute, USA|
|Tobias Wang, PhD||Aarhus University, Denmark|
|Betty S. Pace, MD||Georgia Regents University, USA|
|Jing An, MD, PhD||University of California San Diego, USA|
|Roy Baynes, PhD||Amgen Inc., PhD|
|Lee A. Bulla, Jr, PhD||The University of Texas at Dallas, USA|
|Mark H. Kirschbaum, MD||City of Hope National Cancer Center, Duarte, California, USA|
|Chulso Moon, MD, PhD||Lutherfield, Maryland, USA|
|Jeffrey Schlom, PhD||National Cancer Institute, USA|
- Aims and scope
- Editorial Policy
- Types of Articles
- How to submit a manuscript
- How to Prepare a Manuscript
- Proofs, Page/Color Charges and Eprints
These instructions comply with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals formulated by the International Committee of Medical Journal Editors (for further details, see the ICMJE site).
The journal Experimental Biology and Medicine is offering an English review service for authors submitting manuscripts. For more information about this low-cost option contact email@example.com.
All manuscripts should be submitted to: https://mc.manuscriptcentral.com/ebm
Please read the following instructions prior to submitting your manuscript:
1. Aims and scope
Experimental Biology and Medicine is particularly appropriate for publication of papers that are multidisciplinary in nature, are of potential interest to a wide audience, and represent experimental medicine in the broadest sense of the term. However, manuscripts reporting novel findings on any topic in the realm of experimental biology and medicine are most welcome. We particularly encourage submission of manuscripts that describe results of studies that require an interdisciplinary approach to biomedical issues. Categories currently listed in EBM are: Anatomy/Pathology; Biochemistry and Molecular Biology; Cell and Developmental Biology; Bioimaging; Biomedical Engineering; Bionanoscience;Endocrinology and Nutrition; Genomics, Proteomics, and Bioinformatics; Immunology/Microbiology/Virology; Neuroscience; Pharmacology and Toxicology; Physiology; Stem Cell Biology; Structural Biology; Systems Biology and Translational Research. Authors should indicate their preference of category, although the final decision of reviewing Associate Editor and section Editorial Board rests with the Editor-in-Chief.
For more information on the topics we are interested in publishing in Experimental Biology and Medicine, please click here.
Covering letter: The covering letter is important. To help the Editor in his preliminary evaluation, please indicate why you think the paper suitable for publication; the letter should explain how your paper is innovative, provocative, timely, and of interest to a broad audience. The letter should list any paper on related topics by any of the authors that have been published within the past year or that are in review or in press. The letter must state that the non-signing author(s) have read and approved the manuscript. Any person cited in the manuscript as a source of "personal communication" or "unpublished data" must provide signed approval of such citation.
Peer Review: Two reviewers will generally evaluate each manuscript on the basis of scientific rigor of the experimental design, adequacy of the data, validity of the conclusions, importance and originality of the studies, adequacy of the literature citations, clarity of the presentation, and interest to the Journal's readership. Manuscripts may be returned to the authors without detailed review if, in the opinion of the Editor-in- Chief, they fall outside the scope of interests of the Journal's readership or if they are not written in clear, concise and grammatical English.
Manuscripts will be given a quality (priority) ranking by each reviewer. Those manuscripts with low priority rankings will not be accepted even though they may have been classed as generally acceptable. If reviewers differ significantly in their opinions, decision will be based on the priority rankings and/or the opinion of an additional reviewer (arbiter). Manuscripts returned after revision based upon reviewers' comments will be sent back to the original reviewers together with the authors' responses.
The reviewers' comments will be held in confidence except as follows: (a) the reviewers' comments may be sent, in whole or in part, to the corresponding author;(b)after revision, each reviewer's comments will be sent, in whole or in part, to the other reviewers of the manuscript: and (c) in the event that there is a significant difference in opinion between or among the reviewers, the manuscript may be sent to an additional reviewer (arbiter) together with the comments, in whole or in part, of the other reviewers. In all cases, anonymity of the reviewers will be maintained.
Ethical Approval: All research submitted for publication must be approved by an ethics committee.
Use of Human and Animal Subjects and Recombinant DNA: Studies involving human subjects must conform to the ethical standards set by the Belmont Report, Ethical Principles and Guidelines for the Protection of Human Subjects of Research; must have been reviewed and approved by the appropriate institutional Review Board (IRB); and must be presented in such a manner as to assure preservation of the anonymity of the subjects. It must be stated in the Materials and Methods section of the article that the study had been approved by the responsible IRB and that informed consent was obtained from research subjects or it must be explained why IRB review and /or informed consent were not required.
It is the Journal's policy that all studies involving the use of animals be conducted in compliance with applicable laws and regulations as well as the principles expressed in the National Institutes of Health, USPHS, Guide for the Care and Use of Laboratory Animals, and that the studies be conducted on animals that were lawfully acquired. Use of animals must have been approved by the Institution's Animal Care and Use Committee (IACUC) and this must be stated in the Materials and Methods section of the article. If the study was conducted in a jurisdiction where such review is not required, this should be noted in the Materials and Methods section. Experiments involving recombinant DNA must have been reviewed and approved as required by applicable laws and regulations.
Financial Support and Conflict of Interest: All grant, contract and industrial support of the work included in the manuscript must be acknowledged in a footnote to the title of the manuscript. Commercial relationships of any of the authors that might be viewed as representing a conflict of interest must be disclosed in a footnote to the applicable author's name. Such disclosure should be made on a separate page as it will not be sent to reviewers or influence editorial decisions but will be included in the published paper.
Authorship: Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.
The list of authors should include all those who can legitimately claim authorship. This is all those who:
- Made a substantial contribution to the concept and design, acquisition of data or analysis and interpretation of data,
- Drafted the article or revised it critically for important intellectual content,
- Approved the version to be published.
Authors should meet the conditions of all of the points above. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.
Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.
Acknowledgements: All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.
Writing Assistance: Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance”).
It is not necessary to disclose use of language polishing services.
Plagiarism Policy: The knowing duplication of published work without appropriate attribution will not be tolerated. This policy covers all material, whether in the form of text, tables, figures or other exhibits, which has been published or is being considered for publication in another journal, and applies to the published work of the submitting author(s) as well as the work of other investigators.
The Journal and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarised other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.
Three levels of plagiarism are covered by this policy, with progressively more severe sanctions: Level one: Limited duplication of text from the authors' own published work, with somewhat more relaxed stringency for materials and methods: In these cases, the manuscript will be returned to the authors with instructions to rewrite/rephrase the duplicated text, before publication of the submission may proceed. If the materials and methods are heavily duplicated, the authors could be advised to reference their published work, thereby shortening that section. Level two: Substantial duplication of an author's own work, or significant duplication of the work of others, will result in rejection of the manuscript or retraction after publication. Level three: Duplication of an author's own work so extensive that it could be considered an attempt to publish the same work twice [dual or redundant publication], or lifting of large chunks of text or data from the work of others, will result in rejection of the manuscript or retraction after publication and, in addition, contacting the appropriate officials at the author's institution.
Submitted manuscripts which, following the initial review, have a likelihood of eventual publication in EBM, will be evaluated by advanced plagiarism detection software, which systematically compares the manuscript against an extensive database of published literature. If the software identifies possible plagiarism, further investigation will be conducted by the Associate Editor of the assigned section of EBM. Findings of potential plagiarism requiring one of the sanctions described above will be forwarded to the Editor in Chief for further review. Every effort will be made to conduct these reviews in a careful, fair and impartial manner, to avoid inappropriate imposition of sanctions. EBM urges submitting authors to avoid duplication either of their own work or that of others, and recommends authors evaluate their manuscripts with plagiarism-detecting software before submitting their work to EBM.
Permissions: All previously published material must be accompanied by the written consent to reproduction of the copyright holder. An acknowledgement of permission should be included at the relevant point in the paper, and a full reference to the original place of publication should be included in the reference list.
Copyright: Authors of accepted manuscripts will be required to allocate copyright to the Society for Experimental Biology and Medicine (SEBM).
Open Access and Author Archiving: Experimental Biology and Medicine offers optional open access publishing via the SAGE Choice program. For more information please visit the SAGE Choice website. For information on funding body compliance, and depositing your article in repositories, please visit SAGE Publishing Policies on our Journal Author Gateway.
Disclaimer: Articles and other materials published in Experimental Biology and Medicine represent the opinions of the author(s) and should not be construed to reflect the opinions of the Editor(s) or the Society.
Authors of manuscripts describing original nucleotide or amino acid sequences must submit the sequence to Gen Bank and obtain an accession number from Gen Bank before publication of the manuscript. The accession number should be included in the manuscript as a footnote or in the appropriate figure legend.
When, as a result of reviewers' comments, it is necessary to revise a manuscript, it is recommended that, unless additional studies are required, the authors should resubmit the revised manuscript promptly; a delay of longer than four months may result in the revised manuscript receiving a lower priority.
If you have any questions regarding submission, please contact the SEBM office: Tel: 201-962-3519 | Fax: 201-962-3522 | e-mail: firstname.lastname@example.org.
Original Research Articles: Manuscripts are accepted for review with the understanding that the same work has not been submitted or published elsewhere and, if accepted by EBM, will not be submitted or published elsewhere. If evidence of dual submission is found, the manuscript will be rejected or, if published, retracted.
Unnecessary subdivision of a study into several manuscripts is not acceptable. If any material published previously is included, for clarity or other reasons, this should be indicated with appropriate citation in the manuscript.
One copy of any material that might be regarded as "duplicate publication" such as preliminary reports (including reviews, symposia and proceedings) or other publications (submitted, in press or published) containing data or other material included in the submitted manuscript, must be sent to the Editor when the manuscript is submitted. Clearly label such material so as to avoid any confusion with the submitted manuscript. Normally it is regarded as acceptable to include in a detailed journal article material that has been presented previously in summary form in reviews, symposia, or conferences, provided appropriate citation is included.
Brief Communications: Manuscripts describing focused studies that are concise and of high impact to a field will be published as Brief Communications. This format is intended for the presentation of scientifically sound and novel research in a clear and concise fashion. The body of the paper should not exceed nine (9) pages of double-spaced text with references. Tables and Figures must also be kept to a minimum (no more than four). Formatting should otherwise follow the requirements for Original Research Articles.
Minireviews: The journal publishes review articles under the section heading "Minireviews." Although there is no page limit, the reviews are generally short (~20 pages of double-spaced text with references). They should reflect the state-of-the-art of the area being reviewed and often include a brief history of the field. There is no need to include an exhaustive literature survey. Emphasis upon a particular hypothesis or point of view or upon the personal opinions or interpretation of the writer or upon the work of the writer's laboratory is appropriate, provided that this focus is clearly indicated in the paper. Most reviews are submitted in response to an invitation from the Editor-in-Chief, and are subjected to the usual review process prior to publication. Unsolicited reviews and reviews solicited by the Associate Editors need to be approved by the Editor-in-Chief before receiving peer review.
Comments: The Journal, at the Editor-in-Chief's discretion, will publish, under the section heading "Comments ", letters or essays from readers discussing articles that have recently appeared in the Journal or other timely topics of interest to the Journal's readership. The author of a letter or essay which is published accepts full responsibility for the contents of the letter. Letters discussing a published article may for example include supporting information, clarifications, criticisms, corrections, alternate interpretations or perspectives. Such letters will be sent to the corresponding author of that article prior to publication. If the corresponding or other author wishes, her/his response will be published together with the original letter. At the discretion of the editor, essays or letters discussing controversial issues may be sent to persons representing alternative viewpoints who will be encouraged to provide responses. If the Editor decides to publish such responses, they will be sent to the original author for comments prior to publication. In some cases, the Editor-in-Chief may send a letter or essay for outside review prior to deciding whether to publish it. The Society reserves the right to edit these communications without materially changing their meaning.
Only manuscripts submitted via the online manuscript submission and peer review site, which can be found at https://mc.manuscriptcentral.com/ebm be considered for publication.
Please note the following forms must be completed on submission:
Assistance with English
If English is not your native language, you may find it helpful to obtain assistance in writing your papers before submitting them to EBM. This may not only save time in the review process but also increase the accuracy of your submission. EBM offers low-cost English services for authors.
More information about EBM English Services at http://www.EBMEnglishServices.squarespace.com
Tables and figures must be submitted as separate individual files, in which case the files should be uploaded in the following order: (1) main text, including title page, abstract, references and figure legend(s); (2) tables; (3) figures; and (4) supplementary files.
File formats: Text files must be saved in .doc or .rtf format. Other suitable formats include .tif, .jpg, and ppt for photographic images, .xls for graphs produced in Excel, and .eps for other line drawings.
Formatting: Manuscripts should be as concise as possible, yet sufficiently detailed to permit critical appraisal, and should generally not exceed 40 typed pages (including tables, charts and references). They must be submitted using double line-spaced, unjustified text throughout, with headings and subheadings in bold case. Press 'Enter' only at the end of a paragraph, list entry or heading.
Title page: The first page should contain the full title of the manuscript, a short title, the author(s) name(s)and affiliation(s), and the name, postal and email addresses of the corresponding author, as well as a full list of declarations.
The title should be a declarative statement of key findings and should be limited to 15 words. Use of abbreviations in the title should generally be avoided. Research articles should be divided into an Abstract, Keywords, Introduction, Materials and Methods, Results, and Discussion sections.
Abstract: An abstract of no more than 300 words must accompany all articles and should not be structured.
Impact Statement: An Impact Statement is required for all submissions. It should be no more than 150 words and will be included as a boxed statement on the first page of the article, separate from the Abstract. The Impact Statement is not a restating of the abstract. It should address the following:
- Why is the work submitted important to the field?
- How does the work submitted advance the field?
- What new information does this work impart to the field?
- How does this new information impact the field?
Tables. Tables must be prepared using the Table feature of the word processor. Tables should not duplicate information given in the text, should be numbered with Arabic numerals and cited consecutively in the text. Each table should be titled and double-spaced on a separate sheet. Refer to current issues of Experimental Biology and Medicine for the acceptable style of tables. The title of each table should clearly indicate the nature of the contents, and sufficient experimental detail should be included in footnotes to the entries in the table to permit the reader to interpret the results without reference to the text. Units must be clearly indicated for each of the entries in the table.
Figures. All figures should be cited consecutively by Arabic numerals in the text with figure legends typed on a separate sheet. Legends should contain sufficient experimental detail to permit the figures to be interpreted without reference to the text. Units should be clearly indicated in the figures themselves. All figures and illustrations are to be submitted individually in such form as to permit photographic reproduction without retouching or redrawing. Line drawings should be no larger than 8.5 x 11.5 inches overall (21 x 27.5 cm). The lettering should be large enough to allow a reduction of two thirds.
Line drawings should be produced electronically and clearly labeled using sans serif font such as Arial. Graphs may be supplied as Excel spreadsheets (one per sheet). Other line drawings should be supplied in a suitable vector graphic file format (e.g. .eps).
All photographic images should be submitted in camera-ready form (i.e. with all extraneous areas removed), and where necessary, magnification should be shown using a scale marker. Photographic images must be supplied at high resolution, preferably 600 dpi. Images supplied at less than 300 dpi are unsuitable for print and will delay publication. The preferred file format is .tif.
Manufacturer names: Please note that when manufacturer names are used in the text, the location (city, state, country) of the manufacturer should also be included.
"Statement of Author Contributions and Acknowledgments" should be typed on a separate page and placed at the end of the text pages.
Authors must include a statement that specifies the actual contribution of each coauthor to the completed work. Formatting of the Statement of Author Contributions is illustrated by the following example:
"All authors participated in the design, interpretation of the studies and analysis of the data and review of the manuscript; MPV, MNS, KAM, and YZ conducted the experiments, RJS supplied critical reagents [or animals] (specify), RAS and WEZ wrote the manuscript, and XYZ contributed [other] (specify)."
Individuals whose contribution does not reach the level required for their inclusion as an author should be acknowledged in the traditional way, with their full names(s) given. For example, "The authors thank Dr. John Doe for advice in statistical analysis".
The corresponding author must verify that all individuals who made contributions to this study are included either as authors or are acknowledged at the end of the paper.
References: Citations should be used to provide appropriate attribution and credit to previous investigators. Authors are responsible for verifying them against the original source material. Extensive citation should be avoided, if possible, while adhering to the applicable conventions of the scientific community. Authors are responsible for obtaining permission to reproduce from the appropriate sources cited in the text. References should be arranged numerically at the end of the manuscript and cited in the text with superscript numerals. The references should be numbered consecutively in order of their citation and include the names and initials of all authors. Publications for which no author is apparent may be attributed to the organization from which they originate. Simply omit the name of the author for anonymous journal articles - avoid using 'Anonymous'. Experimental Biology and Medicine uses a modified version of the Vancouver referencing system; examples are shown below:
- Zhang X, Wang J, Fan Y, Yang L, Wang L, Ma J. Zinc supplementation attenuates high glucose-induced epithelial-to-mesenchymal transition of peritoneal mesothelial cells. Biol Trace Elem Res 2012; 150: 229–35
- Weatherall D, Clegg J. The molecular pathology of the thalassaemias. The Thalassaemia Syndromes, 4th ed. Oxford: Wiley-Blackwell, 2001, pp. 133–91
"Personal communication", "unpublished" and "submitted" must be excluded from the reference list and cited in a footnote. If a manuscript being cited has been accepted for publication, include it in the reference list, giving journal, volume, year as available. In general, citation of numerous abstracts is discouraged, although acceptable if necessary to provide proper attribution or credit.
Trade name, popular name or abbreviation when first used must be preceded by the chemical, scientific or technical name; thereafter, any of these names or abbreviations may be used. Trade names should begin with a capital letter. Structural formulas of chemicals should be used only when absolutely necessary.
Abbreviations: Symbols and abbreviations should be those currently in use. Authors should not create new abbreviations and acronyms.
Units: All measurements should be expressed in SI units.
Statistics: If preparing statistical data for publication, please read the statistical guidelines.
1. Proofs will be sent by email to the designated corresponding author as a PDF file attachment and should be corrected and returned promptly; corrections should be kept to a minimum. Authors will be charged for excessive changes.
2. Colored illustrations will be published only if the authors cover the costs. There is no charge to member and non-member authors for online color.
3. Authors are required to pay a part of the cost of publication in the form of a page charge of $70 per page. There will be no page charges for articles where the first or corresponding author is an SEBM member in good standing at the time of manuscript submission. In addition, these papers are assessed a reduced color print fee. Authors lacking funding from grant or other sources may apply at the time of submission for a waiver of page charges. Apply for a waiver of page charges on institutional letterhead at the time of submission. The letter can be sent electronically to email@example.com or faxed to 201-962-3522. Applications must be endorsed by a senior institutional official verifying that no funds are available for paying page charges. A waiver of page charges will not be granted once an initial decision has been rendered on the manuscript. Once a waiver has been approved and a paper published authors may not request a waiver for any future manuscripts. Reprint orders of 1,000 or more should be discussed with the publisher and authors are generally expected to discourage circulation of reprints for commercial purposes.
SAGE provides authors with access to a PDF of their final article. For further information please visit the SAGE Journal Author Gateway